{"id":272723,"date":"2025-10-02T20:18:19","date_gmt":"2025-10-02T20:18:19","guid":{"rendered":"https:\/\/www.europesays.com\/us\/272723\/"},"modified":"2025-10-02T20:18:19","modified_gmt":"2025-10-02T20:18:19","slug":"fulgent-genetics-hits-new-52-week-high-at-23-57","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/272723\/","title":{"rendered":"Fulgent Genetics Hits New 52-Week High at $23.57"},"content":{"rendered":"

Fulgent Genetics, Inc.<\/a> has achieved a new 52-week high, reflecting a year-over-year performance increase. With a market capitalization of USD 682 million, the company faces challenges, including a negative return on equity and no dividend yield, as it navigates the competitive biotechnology sector.
\n <\/p>\n

Fulgent Genetics, Inc.<\/a>, a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 23.57 on October 1, 2025. This achievement marks a notable increase from its 52-week low of USD 14.57, reflecting a year-over-year performance of 15.37%. <\/p>\n

With a market capitalization of USD 682 million, Fulgent Genetics operates in a competitive industry where it continues to navigate various market dynamics. The company’s financial metrics indicate a challenging environment, as it currently reports a negative return on equity of -2.87% and a debt-to-equity ratio of -0.26. Additionally, the company does not offer a dividend yield, which is consistent with its loss-making status.<\/p>\n

As Fulgent Genetics continues to evolve within the biotechnology landscape, its recent price movement underscores the ongoing developments and trends impacting its market position. The stock’s performance relative to the S&P 500, which has seen a 16.09% increase over the same period, highlights the broader market context in which Fulgent operates. <\/p>\n","protected":false},"excerpt":{"rendered":"Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a year-over-year performance increase. With a market capitalization…\n","protected":false},"author":3,"featured_media":272724,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[815,159,67,132,68],"class_list":{"0":"post-272723","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115306424726497099","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/272723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=272723"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/272723\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/272724"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=272723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=272723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=272723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}